Assessing quality of life in Alzheimer's disease: Implications for clinical trials

If you need an accessible version of this item, please submit a remediation request.
Date
2016-12-13
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Elsevier
Abstract

Introduction

Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials. Methods

Using data from 1322 patients enrolled in two phase-III studies (EXPEDITION 1 [NCT00905372] and 2 [NCT00904683]) of intravenous solanezumab in outpatients with mild AD dementia, correlations between patient- and caregiver-assessed QOL and between QOL and clinical outcome measures were examined. Longitudinal effects of solanezumab over 80 weeks were explored, controlling for patient and caregiver baseline characteristics. Results

Caregivers rated patients' QOL worse than did patients themselves. Patients' QOL was correlated, albeit modestly, with clinical/health measures. Patients' QOL changed minimally over 80 weeks, although a treatment effect of solanezumab on QOL was detected. Discussion

Further investigations are needed to determine the optimal measures with which to quantify and qualify QOL of patients with mild AD.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Kahle-Wrobleski, K., Ye, W., Henley, D., Hake, A. M., Siemers, E., Chen, Y.-F., & Liu-Seifert, H. (2017). Assessing quality of life in Alzheimer’s disease: Implications for clinical trials. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 6, 82–90. http://doi.org/10.1016/j.dadm.2016.11.004
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}